Suppliers and packagers for generic pharmaceutical drug: CARBACHOL

CARBACHOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alcon	MIOSTAT	carbachol	SOLUTION;INTRAOCULAR	016968	NDA	Alcon Laboratories, Inc.	0065-0023-15	12 VIAL, GLASS in 1 CARTON (0065-0023-15) / 1.5 mL in 1 VIAL, GLASS	1974-04-15

CARBACHOL Suppliers: Who Manufactures and Supplies Carbachol (US and Global) for Pharmaceutical, Hospital, and Research Use

Last updated: May 23, 2026

Carbachol (carbachol chloride; miotic/cholinergic agent) is supplied in multiple dosage forms, including ophthalmic solutions. Supplier coverage is driven by which branded product and concentration is being sourced, and by regulatory status and import availability. This write-up compiles the practical supplier set for procurement and downstream sourcing using publicly listed manufacturer and distributor roles (label holders, listed manufacturers, and distribution channels).

What companies supply CARBACHOL (carbachol chloride) ophthalmic and injectable products?

Primary supplier categories

1. Label holder / marketing authorization holder (brand owner and responsibility for product release under relevant markets).
2. Manufacturer of record (API and/or finished dosage form manufacturing, often via contract manufacturing).
3. Importer / local distributor (common in ophthalmic and hospital market channels).
4. Contract packers / sterile filling sites (for ophthalmic and parenteral forms).

Procurement implication: A “supplier” in purchasing systems can mean the distributor, the label holder, or the actual finished-goods manufacturer. For IP, quality, and sourcing risk, focus on the manufacturer of record for the target strength and dosage form.

Which suppliers make carbachol ophthalmic solutions (strength-specific sourcing)?

Ophthalmic product reality Carbachol is most commonly encountered as an ophthalmic solution used for miosis in ophthalmic surgery and for certain ocular indications. For procurement, the key differentiators are:

• strength (for example, common market strengths are typically 0.01% to 0.5% depending on product and country),
• bottle type and package size,
• sterility assurances and preservative system.

Supplier mapping approach for sourcing

• Identify the exact strength and dosage form on the purchase specification.
• Pull the manufacturer name from the US label, EU labeling, or market authorization dossier.
• Verify NDC (US) or equivalent regulatory identifier in the target geography.
• Confirm whether the supply is domestic manufacture or imported.

Who supplies carbachol chloride injectable and parenteral forms?

Carbachol parenteral products exist in some jurisdictions but are less standardized in availability than ophthalmic. Parenteral sourcing risk concentrates in:

• sterile manufacturing capacity,
• batch release testing,
• cold chain requirements (if any for the specific formulation),
• availability of excipients and sterile filtration components.

For procurement, the decisive fields are the site of manufacture and release testing location on the label.

Are carbachol suppliers different by country or regulatory market?

Yes. Carbachol supply is split across:

• US market (coverage via NDC-labeled products and established distributor networks).
• EU and UK (authorization-based supply with local marketing authorization holders and parallel distribution in some lanes).
• Emerging markets (often importer-led distribution and lower transparency on manufacturing tiering).

Procurement and quality frameworks should be aligned to the regulatory market where the product is actually sourced.

What is the US supply landscape for carbachol (NDC-based sourcing)?

In the US, supplier visibility is typically strongest through:

• NDC-associated label information (manufacturer and distributor roles),
• pharmacy wholesaler listings,
• official drug product databases and label pulls.

Procurement action that matters: Ensure the purchased SKU matches the NDC and label strength, since carbachol has multiple variants and formulation differences across products.

What wholesalers/distributors carry CARBACHOL in the supply chain?

For many legacy and niche drugs, distribution is handled through national wholesalers with recurring SKU availability. Common distributor roles in practice include:

• national pharmaceutical distributors that replenish hospital and retail systems,
• regional distributors for ophthalmology practices,
• direct-to-hospital allocations where available.

Procurement action that matters: Even when you buy from a wholesaler, the drug product’s manufacturer is determined by the branded SKU you receive. Align purchasing controls to lot traceability and label manufacturer.

Which API suppliers feed finished carbachol products?

API supply is more opaque than finished-goods labeling. For sourcing, most buyers do not contract directly for carbachol API unless they qualify an alternative manufacturing pathway. The procurement controls that matter are:

• API CoA traceability to the finished-goods lot,
• DMF-linked verification where applicable,
• inspection history for sterile and non-sterile operations (depending on dosage form).

How many suppliers can realistically support carbachol production (supply resiliency)?

Carbachol’s supply resiliency depends on how many finished-goods sites are actively releasing product for the specific strength and dosage form. In practice:

• ophthalmic strengths often have at least a small number of releasable sources,
• parenteral availability is narrower and more subject to manufacturing disruptions,
• import dependency rises in jurisdictions where local finished-goods manufacture is limited.

Procurement implication: Use at least two independent SKU sources for critical use cases (when label and regulatory compatibility is confirmed).

What supplier due diligence steps reduce quality and supply risk for CARBACHOL?

• Confirm manufacturer of record and site of manufacture for every PO.
• Require lot-level CoA tied to the received lot number.
• Check sterility assurance and preservative system alignment for ophthalmic use.
• Validate storage conditions and temperature excursions at receipt.
• Lock change control terms in supplier contracts for manufacturer/site and formulation changes.

Key Takeaways

• “CARBACHOL suppliers” vary by dosage form and strength; sourcing must be SKU-specific, not brand-level.
• For ophthalmic carbachol, prioritize the label manufacturer of record and the NDC/market authorization identifier tied to the exact concentration.
• In the US and many export markets, distribution is often via major wholesalers, but quality and manufacturing responsibility stays with the label manufacturer.
• Supplier resilience is driven by how many sites actively release the exact strength and dosage form; maintain dual-source purchasing for critical use.

FAQs

1) Who are the manufacturer-of-record suppliers for carbachol ophthalmic solutions?
Answer: Manufacturer-of-record varies by exact strength and product SKU; procurement should use the product label manufacturer tied to the NDC/authorization.

2) Can I source carbachol from multiple wholesalers without changing manufacturing?
Answer: Yes for distribution, but it depends on the received SKU. The same wholesaler can ship different label/manufacturer lots.

3) Are carbachol injectable products supplied by the same manufacturers as ophthalmic?
Answer: Not necessarily. Sterile manufacturing capability and dosage-form requirements can be different by site.

4) What supply chain risks are most common for carbachol?
Answer: Limited finished-goods sources for specific strengths, import dependency, and manufacturing interruptions at sterile or sterile-adjacent sites.

5) How should hospitals specify carbachol purchases to avoid mismatched strength or formulation?
Answer: Specify the NDC (US) or full regulatory identifier, strength, container configuration, preservative system, and manufacturer of record.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (search by carbachol). U.S. Food and Drug Administration.
2. FDA. Drug Databases and Product Information: Label and NDC directory resources (search carbachol products). U.S. Food and Drug Administration.
3. EMA. European public assessment reports and product information for carbachol-containing products (search by carbachol chloride). European Medicines Agency.